JPMorgan Chase & Co. Issues Positive Forecast for Royalty Pharma (NASDAQ:RPRX) Stock Price

Key Points

• JPMorgan raised its price target on Royalty Pharma to $58 (from $50) and kept an “overweight” rating, implying roughly a 15.8% upside; the stock’s consensus analyst rating is “Buy” with an average target near $51.43.
• Q1 results were mixed: EPS beat expectations and management sounded confident, but reported revenue (~$631M) came in well below some street estimates (~$880M), which could pressure near‑term cash visibility and limit upside given a P/E around 37.
• Insiders and institutions are active: the CFO sold shares under a Rule 10b5‑1 plan (part of ~139K shares sold in the last 90 days), insiders own ~18.8% and institutional holders own ~54.4% of the stock; shares were trading about $50.11 at the time of the report.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) had its price objective increased by equities researchers at JPMorgan Chase & Co. from $50.00 to $58.00 in a report released on Thursday,Benzinga reports. The firm currently has an "overweight" rating on the biopharmaceutical company's stock. JPMorgan Chase & Co.'s price target would suggest a potential upside of 15.75% from the stock's current price.

A number of other analysts have also weighed in on RPRX. UBS Group increased their target price on Royalty Pharma from $51.00 to $57.00 and gave the stock a "buy" rating in a research note on Tuesday, April 21st. Weiss Ratings upgraded Royalty Pharma from a "buy (b-)" rating to a "buy (b)" rating in a research note on Friday, May 1st. Morgan Stanley increased their target price on Royalty Pharma from $61.00 to $63.00 and gave the stock an "overweight" rating in a research note on Friday, April 10th. Citigroup increased their target price on Royalty Pharma from $48.00 to $50.00 and gave the stock a "buy" rating in a research note on Tuesday, January 27th. Finally, Wall Street Zen lowered Royalty Pharma from a "strong-buy" rating to a "buy" rating in a research note on Saturday, February 14th. Seven investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $51.43.

Royalty Pharma Price Performance

Shares of NASDAQ RPRX traded down $0.61 during midday trading on Thursday, reaching $50.11. 2,684,092 shares of the stock traded hands, compared to its average volume of 3,504,168. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.40 and a quick ratio of 2.40. The stock has a market capitalization of $28.91 billion, a PE ratio of 37.12, a P/E/G ratio of 3.22 and a beta of 0.40. Royalty Pharma has a one year low of $32.15 and a one year high of $51.65. The company's 50 day moving average is $47.52 and its 200 day moving average is $42.66.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its earnings results on Wednesday, February 11th. The biopharmaceutical company reported $1.46 EPS for the quarter, beating analysts' consensus estimates of $1.33 by $0.13. Royalty Pharma had a return on equity of 28.21% and a net margin of 32.38%.The firm had revenue of $621.99 million during the quarter, compared to the consensus estimate of $839.97 million. On average, equities research analysts anticipate that Royalty Pharma will post 5.08 earnings per share for the current year.

Insider Activity at Royalty Pharma

In other news, CFO Terrance P. Coyne sold 34,791 shares of the firm's stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $49.78, for a total transaction of $1,731,895.98. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 139,164 shares of company stock worth $6,624,902 in the last 90 days. Company insiders own 18.84% of the company's stock.

Hedge Funds Weigh In On Royalty Pharma

Several institutional investors have recently made changes to their positions in the company. SEB Asset Management AB purchased a new position in shares of Royalty Pharma during the first quarter valued at $12,967,000. Swiss National Bank boosted its position in Royalty Pharma by 5.8% during the first quarter. Swiss National Bank now owns 1,191,100 shares of the biopharmaceutical company's stock valued at $57,137,000 after purchasing an additional 65,700 shares in the last quarter. Assetmark Inc. boosted its position in Royalty Pharma by 58.8% during the first quarter. Assetmark Inc. now owns 5,858 shares of the biopharmaceutical company's stock valued at $281,000 after purchasing an additional 2,170 shares in the last quarter. Financiere des Professionnels Fonds d investissement inc. boosted its position in Royalty Pharma by 15.5% during the first quarter. Financiere des Professionnels Fonds d investissement inc. now owns 32,413 shares of the biopharmaceutical company's stock valued at $1,555,000 after purchasing an additional 4,356 shares in the last quarter. Finally, Bessemer Group Inc. boosted its position in Royalty Pharma by 34.7% during the first quarter. Bessemer Group Inc. now owns 1,094 shares of the biopharmaceutical company's stock valued at $53,000 after purchasing an additional 282 shares in the last quarter. Hedge funds and other institutional investors own 54.35% of the company's stock.

Key Headlines Impacting Royalty Pharma

Here are the key news stories impacting Royalty Pharma this week:

• Positive Sentiment: Company raised full‑year 2026 Portfolio Receipts guidance and reported portfolio/royalty receipt growth and strong operating cash, signaling durable cash generation that supports the business model. Royalty Pharma reports first quarter 2026 results
• Positive Sentiment: Q1 EPS beat expectations (reported $1.30 vs. consensus ~$1.22) and the company showed healthy margins and ROE, which supports earnings durability. Royalty Pharma (RPRX) Q1 Earnings and Revenues Surpass Estimates
• Neutral Sentiment: Management struck an upbeat, confident tone on the Q1 earnings call and accompanying presentation — useful context for guidance durability but largely reiterative rather than containing new pipeline deals. Royalty Pharma’s Earnings Call Signals Confident Growth
• Negative Sentiment: Reported revenue ($631M) was materially below some street estimates (~$880M), which raises questions about near‑term cash flow visibility from specific royalty streams and likely weighed on sentiment. Press Release / Q1 2026 Report
• Negative Sentiment: Shares recently hit a 52‑week high, so some of the pullback appears to be profit‑taking/rotation after the run; valuation (P/E ~37) may also limit upside absent clearer revenue upside. Royalty Pharma PLC (RPRX) Hit a 52 Week High, Can the Run Continue?

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company's transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.